CHAMPIONS ONCOLOGY, INC. Revenue
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Revenue of $15.23 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-09-11
- CHAMPIONS ONCOLOGY, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-07-31 was $15.23M, a 8.84% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-04-30 was $13.84M, a 11.98% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-01-31 was $16.56M, a 2.82% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-10-31 was $15.04M, a 11.46% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. revenue from contract with customer, excluding assessed tax for fiscal 2026 was $59.42M, a 4.36% increase from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $56.94M, a 13.54% increase from fiscal 2024.
- CHAMPIONS ONCOLOGY, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $50.16M, a 6.90% decline from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $53.87M, a 9.69% increase from fiscal 2022.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-07-31 | $15.23M 10-Q · filed 2026-09-11 | $29.07M derived: sum of 2 quarters · filed 2026-09-11 | $45.63M derived: sum of 3 quarters · filed 2026-09-11 | $60.66M derived: sum of 4 quarters · filed 2026-09-11 |
| 2026-04-30 | $13.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $30.39M derived: sum of 2 quarters · filed 2026-07-27 | $45.43M derived: sum of 3 quarters · filed 2026-07-27 | $59.42M 10-K · filed 2026-07-27 |
| 2026-01-31 | $16.56M 10-Q · filed 2026-03-12 | $31.59M derived: sum of 2 quarters · filed 2026-03-12 | $45.59M 10-Q · filed 2026-03-12 | $57.94M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-10-31 | $15.04M 10-Q · filed 2025-12-15 | $29.03M 10-Q · filed 2025-12-15 | $41.38M derived: sum of 3 quarters · filed 2026-09-11 | $58.42M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-07-31 | $13.99M 10-Q · filed 2026-09-11 | $26.35M derived: sum of 2 quarters · filed 2026-09-11 | $43.39M derived: sum of 3 quarters · filed 2026-09-11 | $56.88M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-04-30 | $12.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $29.39M derived: sum of 2 quarters · filed 2026-07-27 | $42.88M derived: sum of 3 quarters · filed 2026-07-27 | $56.94M 10-K · filed 2026-07-27 |
| 2025-01-31 | $17.04M 10-Q · filed 2026-03-12 | $30.53M derived: sum of 2 quarters · filed 2026-03-12 | $44.59M 10-Q · filed 2026-03-12 | $58.59M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-10-31 | $13.49M 10-Q · filed 2025-12-15 | $27.55M 10-Q · filed 2025-12-15 | $41.55M derived: sum of 3 quarters · filed 2025-12-15 | $53.57M derived: sum of 4 quarters · filed 2025-12-15 |
| 2024-07-31 | $14.06M 10-Q · filed 2025-09-15 | $28.06M derived: sum of 2 quarters · filed 2025-09-15 | $40.08M derived: sum of 3 quarters · filed 2025-09-15 | $51.66M derived: sum of 4 quarters · filed 2025-09-15 |
| 2024-04-30 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23 | $26.02M derived: sum of 2 quarters · filed 2025-07-23 | $37.59M derived: sum of 3 quarters · filed 2025-07-23 | $50.16M 10-K · filed 2025-07-23 |
| 2024-01-31 | $12.02M 10-Q · filed 2025-03-17 | $23.59M derived: sum of 2 quarters · filed 2025-03-17 | $36.15M 10-Q · filed 2025-03-17 | $49.22M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-10-31 | $11.57M 10-Q · filed 2024-12-16 | $24.13M 10-Q · filed 2024-12-16 | $37.20M derived: sum of 3 quarters · filed 2024-12-16 | $49.98M derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | $12.56M 10-Q · filed 2024-09-13 | $25.63M derived: sum of 2 quarters · filed 2024-09-13 | $38.41M derived: sum of 3 quarters · filed 2024-09-13 | $52.69M derived: sum of 4 quarters · filed 2024-09-13 |
| 2023-04-30 | $13.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-19 | $25.84M derived: sum of 2 quarters · filed 2024-07-19 | $40.13M derived: sum of 3 quarters · filed 2024-07-19 | $53.87M 10-K · filed 2024-07-19 |
| 2023-01-31 | $12.77M 10-Q · filed 2024-03-15 | $27.05M derived: sum of 2 quarters · filed 2024-03-15 | $40.80M 10-Q · filed 2024-03-15 | $53.68M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-10-31 | $14.28M 10-Q · filed 2023-12-13 | $28.03M 10-Q · filed 2023-12-13 | $40.90M derived: sum of 3 quarters · filed 2023-12-13 | $54.10M derived: sum of 4 quarters · filed 2023-12-13 |
| 2022-07-31 | $13.74M 10-Q · filed 2023-09-13 | $26.62M derived: sum of 2 quarters · filed 2023-09-13 | $39.81M derived: sum of 3 quarters · filed 2023-09-13 | $51.60M derived: sum of 4 quarters · filed 2023-09-13 |
| 2022-04-30 | $12.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-24 | $26.07M derived: sum of 2 quarters · filed 2023-07-24 | $37.86M derived: sum of 3 quarters · filed 2023-07-24 | $49.11M 10-K · filed 2023-07-24 |
| 2022-01-31 | $13.19M 10-Q · filed 2023-03-16 | $24.98M derived: sum of 2 quarters · filed 2023-03-16 | $36.23M 10-Q · filed 2023-03-16 | $46.80M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-10-31 | $11.79M 10-Q · filed 2022-12-13 | $23.04M 10-Q · filed 2022-12-13 | $33.60M derived: sum of 3 quarters · filed 2022-12-13 | $44.41M derived: sum of 4 quarters · filed 2022-12-13 |
| 2021-07-31 | $11.25M 10-Q · filed 2022-09-12 | $21.82M derived: sum of 2 quarters · filed 2022-09-12 | $32.63M derived: sum of 3 quarters · filed 2022-09-12 | $42.75M derived: sum of 4 quarters · filed 2022-09-12 |
| 2021-04-30 | $10.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-22 | $21.38M derived: sum of 2 quarters · filed 2022-07-22 | $31.49M derived: sum of 3 quarters · filed 2022-07-22 | $41.04M 10-K · filed 2022-07-22 |
| 2021-01-31 | $10.81M 10-Q · filed 2022-03-15 | $20.93M derived: sum of 2 quarters · filed 2022-03-15 | $30.48M 10-Q · filed 2022-03-15 | $39.22M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-10-31 | $10.12M 10-Q · filed 2021-12-13 | $19.66M 10-Q · filed 2021-12-13 | $28.41M derived: sum of 3 quarters · filed 2021-12-13 | $37.42M derived: sum of 4 quarters · filed 2021-12-13 |
| 2020-07-31 | $9.55M 10-Q · filed 2021-09-13 | $18.30M derived: sum of 2 quarters · filed 2021-09-13 | $27.31M derived: sum of 3 quarters · filed 2021-09-13 | $34.93M derived: sum of 4 quarters · filed 2021-09-13 |
| 2020-04-30 | $8.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-26 | $17.76M derived: sum of 2 quarters · filed 2021-07-26 | $25.39M derived: sum of 3 quarters · filed 2021-07-26 | $32.12M 10-K · filed 2021-07-26 |
| 2020-01-31 | $9.01M 10-Q · filed 2021-03-15 | $16.64M derived: sum of 2 quarters · filed 2021-03-15 | $23.38M 10-Q · filed 2021-03-15 | $31.09M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-10-31 | $7.63M 10-Q · filed 2020-12-14 | $14.36M 10-Q · filed 2020-12-14 | $22.08M derived: sum of 3 quarters · filed 2020-12-14 | $28.51M derived: sum of 4 quarters · filed 2020-12-14 |
| 2019-07-31 | $6.74M 10-Q · filed 2020-09-14 | $14.46M derived: sum of 2 quarters · filed 2020-09-14 | $20.89M derived: sum of 3 quarters · filed 2020-09-14 | |
| 2019-04-30 | $7.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-28 | $14.15M derived: sum of 2 quarters · filed 2020-07-28 | $27.07M 10-K · filed 2020-07-28 | |
| 2019-01-31 | $6.43M 10-Q · filed 2020-03-16 | $19.35M 10-Q · filed 2020-03-16 | ||
| 2018-04-30 | $20.24M 10-K · filed 2019-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |